Brno, Apr. 8, 2022 – CasInvent Pharma, a.s., an early-stage drug discovery company developing a proprietary small-molecule lead compound with anticancer properties, announced that the company has held the first scientific advice at the Czech National Institute for Drug Control (SÚKL).
CasInvent Pharma is currently advancing its lead compound through the late stages of preclinical development, whereas the following studies have been successfully concluded: in vitro genotoxicity tests, ADME studies, in vivo Proof-of-Concept studies in CLL and AML, and maximum tolerated dose studies upon oral administration in mice and rats.
SÚKL has reviewed the provided information by the applicant and stated that the Agency agrees that the planned experiments can support Phase I CTA, in case the results are favorable and the set-up of the advanced GMP is further discussed with the agency.
SÚKL agreed to support CasInvent Pharma during the execution of preclinical program providing the follow-up scientific advices.
© 2024 Casinvent